Castration Resistant, Taxane Naïve Metastatic Prostate Cancer: Current Clinical Approaches and Future Directions

Journal of Urology

Volumn 178, Issue 3 SUPPL., 2007, Pages

  Gignac, Gretchen A ^a,b   Morris, Michael J ^a,b   Hussain, Maha ^c  

^a Sidney Kimmel Center for Prostate and Urologic Cancers   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

androgen; drug therapy; immunotherapy; prostate; prostatic neoplasms; receptors

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ABIRATERONE ACETATE; ANDROGEN; ANDROGEN RECEPTOR; ANSAMYCIN DERIVATIVE; ANTIANDROGEN; ANTINEOPLASTIC ANTIBIOTIC; ATRASENTAN; BEVACIZUMAB; BICALUTAMIDE; CALCITRIOL; DENOSUMAB; DN 101; DOCETAXEL; ENZYME INHIBITOR; ESTRAMUSTINE; EVEROLIMUS; FLUTAMIDE; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE INHIBITOR; IPILIMUMAB; KETOCONAZOLE; MITOXANTRONE; NILUTAMIDE; PLACEBO; PREDNISONE; PROVENGE; TAXANE DERIVATIVE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

APOPTOSIS; ARTICLE; BONE DENSITY; BONE METASTASIS; BONE MINERAL; BONE TURNOVER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CASTRATION; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; IMMUNE SYSTEM; MALE; MEDICAL DECISION MAKING; METASTASIS; MONOTHERAPY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SINGLE DRUG DOSE; TREATMENT PLANNING;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RISK ASSESSMENT; TAXOIDS;

EID: 34547681208     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.04.033     Document Type: Article

References (44)

1. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502
2. Petrylak D.P., Tangen C.M., Hussain M.H., Lara Jr. P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513
3. Smaletz O., Scher H.I., Small E.J., Verbel D.A., McMillan A., Regan K., et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20 (2002) 3972
4. Halabi S., Small E.J., Kantoff P.W., Kattan M.W., Kaplan E.B., Dawson N.A., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 (2003) 1232
5. Berthold D., Pond G., De Wit R., Eisenberger M., and Tannock I. Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. Proc Am Soc Clin Oncol 24 (2006) 221S
6. Kelly W.K., and Scher H.I. Prostate specific antigen decline after antiandrogen withdrawal. J Urol 149 (1993) 607
7. Scher H.I., Liebertz C., Kelly W.K., Mazumdar M., Brett C., Schwartz L., et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 15 (1997) 2928
8. Joyce R., Fenton M.A., Rode P., Constantine M., Gaynes L., Kolvenbag G., et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 159 (1998) 149
9. Schellhammer P.F., Sharifi R., Block N.L., Soloway M.S., Venner P.M., Patterson A.L., et al. Clinical benefits of bicalutamide (Casodex) compared with flutamide (Eulexin) in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology 50 (1997) 330
10. Kassouf W., Tanguay S., and Aprikian A.G. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 169 (2003) 1742
11. Small E.J., Halabi S., Dawson N.A., Stadler W.M., Rini B.I., Picus J., et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22 (2004) 1025
12. Mohler J.L., Gregory C.W., Ford III O.H., Kim D., Weaver C.M., Petrusz P., et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 10 (2004) 440
13. Scher H.I., and Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23 (2005) 8253
14. Taplin M.E., Bubley G.J., Shuster T.D., Frantz M.E., Spooner A.E., Ogata G.K., et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332 (1995) 1393
15. O'Donnell A., Judson I., Dowsett M., Raynaud F., Dearnaley D., Mason M., et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90 (2004) 2317
16. Solit D.B., Zheng F.F., Drobnjak M., Munster P.N., Higgins B., Verbel D., et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8 (2002) 986
17. Schulte T.W., Blagosklonny M.V., Ingui C., and Neckers L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 270 (1995) 24585
18. Basso A.D., Solit D.B., Chiosis G., Giri B., Tsichlis P., and Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 277 (2002) 39858
19. Solit D., Anana M., Valentin G., De la Cruz A., Tong W., and Busam K. Phase I trial of 17-AAG (17-allylamino-1-demethoxygeldanamycin) in patients (pts) with advanced cancer. Proc Am Soc Clin Oncol 22 (2003) 198
20. Workman J.L., and Kingston R.E. Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 67 (1998) 545
21. Chen L., Meng S., Wang H., Bali P., Bai W., Li B., et al. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 4 (2005) 1311
22. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60 (2000) 5165
23. Kelly W.K., Rachon V.M., Curley T., Tong W., O'Connor O., Richardson S., et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity. Proc Am Soc Clin Oncol 21 (2002) 6b
24. Whang Y., Wu X., Suzuki H., Reiter R., Tran C., Vessella R., et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A 95 (1998) 5246
25. Kaper F., Dornhoefer N., and Giaccia A.J. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res 66 (2006) 1561
26. Small E.J., Schellhammer P.F., Higano C.S., Redfern C.H., Nemunaitis J.J., Valone F.H., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24 (2006) 3089
27. Thompson C.B., and Allison J.P. The emerging role of CTLA-4 as an immune attenuator. Immunity 7 (1997) 445
28. Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., and Ledbetter J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174 (1991) 561
29. Carducci M.A., Padley R.J., Breul J., Vogelzang N.J., Zonnenberg B.A., Daliani D.D., et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21 (2003) 679
30. Carducci M., Nelson J., Saad F., Schulman C., Dearnaley D., and Sleep J. Effects of atrasentan on disease progression and biological markers in med with metastatic hormone-refractory prostate cancer: Phase 3 study. Proc Am Soc Clin Oncol 24 (2004) 383
31. Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Yano K., et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253 (1998) 395
32. Brown J.M., Corey E., Lee Z.D., True L.D., Yun T.J., Tondravi M., et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57 (2001) 611
33. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 (2006) 821
34. Ferrer F.A., Miller L.J., Andrawis R., Kurtzman S., Albertsen P.A., Laudone V.P., et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer. J Urol 157 (1997) 2329
35. Duque J.L., Loughlin K.R., Adam R.M., Kantoff P.W., Zurakowski D., and Freeman M.R. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54 (1999) 523
36. Picus J., Halabi S., Rini B.I., Volgelzang N., Whang Y., and Kaplan E. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol 22 (2003) 393
37. Guzey M., Kitada S., and Reed J.C. Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 1 (2002) 667
38. Mantell D.J., Owens P.E., Bundred N.J., Mawer E.B., and Canfield A.E. 1alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 87 (2000) 214
39. Getzenberg R.H., Light B.W., Lapco P.E., Konety B.R., Nangia A.K., Acierno J.S., et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50 (1997) 999
40. Beer T.M. ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int 96 (2005) 508
41. Hussain M., Tangen C.M., Lara Jr. P.N., Vaishampayan U.N., Petrylak D.P., Colevas A.D., et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 23 (2005) 8724
42. Galsky M.D., Small E.J., Oh W.K., Chen I., Smith D.C., Colevas A.D., et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23 (2005) 1439
43. Bai R.L., Paull K.D., Herald C.L., Malspeis L., Pettit G.R., and Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 266 (1991) 15882
44. Tolcher A.W., Chi K., Kuhn J., Gleave M., Patnaik A., Takimoto C., et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 11 (2005) 3854